学术研究

2022-09-29 17:55
研发团队致力于以生物大分子为基础的多基元自组装结构的构建及功能化研究，开发了功能定制化、极具临床转化前景的智能药物载体，为重大疾病诊疗提供了新颖策略。已在Nature Materials，Nature Biotechnology，Nature Communications等国际知名杂志上发表科研论文100余篇。团队首次实现了DNA纳米机器在活体水平肿瘤治疗中的应用（Nat. Biotechnol., 2018, 36, 258），相关成果入选2018年中国科学十大进展；设计开发了在肿瘤免疫治疗中展现良好的治疗效果及长期免疫记忆效果的DNA纳米机器疫苗（Nat. Mater., 2021, 20, 421），相关成果入选2020年“科创中国”先导技术榜单，并申请国内专利以及PCT专利。
1. A DNA nanodevice-based vaccine for cancer immunotherapy. Nat. Mater. 2021,20,421. 2. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nat. Biotechnol. 2018,36,258. 3. A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis. Nat. Commun. 2021,12,358. 4. A Tubular DNA Nanodevice as a siRNA/Chemo-Drug Co-delivery Vehicle for Combined Cancer Therapy. Angew. Chem. Int. Ed. 2021,60,2594. 5. A Tailored DNA Nanoplatform for Synergistic RNAi-/Chemotherapy of Multidrug-Resistant Tumors. Angew. Chem. Int. Ed. 2018,57,15486.